Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
2021
554Background: TALA is a poly(ADP-ribose) polymerase inhibitor approved as monotherapy for adult pts with gBRCA1/2-mutated HER2-negative locally advanced/metastatic BC. We report biomarker analyses...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI